The purpose of this announcement is to conclude pharmaceutical discount agreements pursuant to § 130a.8 SGB V and § 130c.1 SGB V on the active ingredient(s) referred to in point II.1.1). It is not the award of public contracts within the meaning of Directive 2014/24/EU or §§ 97 ff GWB. Any pharmaceutical company can become a contractual partner in accordance with § 4 Abs. 18 AMG. According to the case law of the ECJ, such admission procedures are not necessarily subject to public procurement law, as there is no competition due to the lack of a selection decision. The notice serves as an invitation to conclude discount agreements with conditions that apply equally to all contracting parties and are not dispositive, including the determination of the discount. The contract is concluded by signing the contract documents and submitting the required declarations, which can be requested from the contact point named under I.3).

The earliest start date of the contract is 01.09.2023, provided that the signed contract and the required declarations have been received by the contact point named under I.3) by 09.08.2023. This is what the information in IV.2.2 refers to). In the event of later receipt, the contract shall commence on the 1st of the month following the month of receipt of the signed contract and the required declarations or proofs at the contact point named under I.3), provided that receipt is made by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without the need for termination, as soon as contracts are concluded for the active substance(s) or the active ingredient combination(s) within the framework of an award procedure. The contracts end on 31.08.2025.